Search Results 11-20 of 16757 for tibc

  1. Study of Tipifarnib in Subjects With Relapsed or Refractory Peripheral T-Cell Lymphoma - Mayo Clinic

    Tipifarnib will be administered until disease progression then followed approximately every 12 weeks for survival until either death or 12 months after accrual ...

  2. A Study Evaluating Atezolizumab and Bevacizumab, With or Without Tiragolumab, in Participants With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma (IMbrave152) (SKYSCRAPER-14) - Mayo Clinic

    About this study. The purpose of this study is to assess the efficacy and safety of tiragolumab, an anti-TIGIT monoclonal antibody, when administered in ...

  3. Cancer Treatment! Clinical Trials - Mayo Clinic Research

    The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and preliminary antitumor activity of BG-C137 in ...

  4. Primary Biliary Cholangitis (PBC) Clinical Trials - Mayo Clinic Research

    Primary Biliary Cirrhosis (PBC) is a serious, life--threatening, bile acid related liver disease of unknown cause. Without treatment, it frequently progresses ...

  5. Transforming Healthcare and Outcomes for Children with Inflammatory Bowel Disease - Mayo Clinic

    About this study. The purpose is to put the information into a very large database, which can then be used to improve patient care and achieve the best ...

  6. Paclitaxel, Ifosfamide and Cisplatin (TIP) Versus Bleomycin, Etoposide and Cisplatin (BEP) for Patients With Previously Untreated Intermediate- and Poor-risk Germ Cell Tumors - Mayo Clinic

    The other combination of drugs, bleomycin, etoposide and cisplatin (BEP), is the standard of care treatment for intermediate- and poor-risk germ cell tumors.

  7. Study of Ociperlimab in Combination With Tislelizumab in Advanced Solid Tumors - Mayo Clinic

    About this study. The primary objectives of this study are to assess the safety and tolerability, to determine the maximum tolerated dose (MTD) or maximum ...

  8. Phase II Study of Tipifarnib in Squamous Head and Neck Cancer With HRAS Mutations - Mayo Clinic

    About this study. To determine the antitumor activity of tipifarnib in patients with locally advanced unresectable or metastatic, relapsed and/or refractory ...

  9. A Study of Cemiplimab in Patients With Advanced Basal Cell Carcinoma Who Experienced Progression of Disease on Hedgehog Pathway Inhibitor Therapy, or Were Intolerant of Prior Hedgehog Pathway Inhibitor Therapy - Mayo Clinic

    The primary objective is to estimate the overall response rate (ORR) for metastatic Basal Cell Carcinoma (BCC) (group 1) and for unresectable locally advanced ...

  10. Cancer Clinical Trials - Medical Professionals

    The purpose of this study is to confirm detection of the H3K27M mutation in patient biofluids (CSF, blood, urine, saliva) and uncover the molecular histone ...